Structural Nanomedicine Vaccine Shows Promise Against HPV-Driven Cancers in Preclinical Study

A novel therapeutic vaccine designed using structural nanomedicine principles has demonstrated the ability to slow tumor growth and extend survival in preclinical models of HPV-driven cancers. The research, published in the journal Science Advances, shows that systematically changing the orientation and placement of a single cancer-targeting peptide can lead to formulations that supercharge the immune system's ability to attack tumors.

The vaccine was developed as a spherical nucleic acid (SNA) — a globular form of DNA that naturally enters and stimulates immune cells — with deliberately rearranged components. When tested in humanized animal models of HPV-positive cancer and in patient-derived head and neck cancer tumor samples, one vaccine design consistently outperformed the others, shrinking tumors, extending animal survival and generating larger numbers of highly active cancer-killing T-cells.

The study demonstrates that the specific placement and orientation of the antigen within the SNA is critical for its therapeutic effect. Unlike simple mixtures where the tumor antigen and the adjuvant can be taken up by different cells, the SNA platform ensures that both components are delivered as a single unit to the same antigen-presenting cells. This simultaneous co-delivery within the lymph nodes generates a more powerful and coordinated T-cell response, effectively training the immune system to seek out and destroy cancer cells.

The research highlights the unique advantages of the structural nanomedicine approach, which enables the creation of targeted therapies that co-deliver optimized combinations of therapeutic components directly to individual cells, enhancing drug delivery, stability, potency, and safety. Unlike existing HPV vaccines that prevent infection, this SNA-based approach is designed to treat active, established cancers caused by the virus.

HPV causes most cervical cancers and a rapidly growing portion of head and neck cancers. While existing HPV vaccines can prevent the viral infection, they do not help patients fight cancer after it has already developed. The therapeutic vaccines train the immune system's most potent defense — CD8 "killer" T-cells — to recognize and destroy HPV-positive cancer cells.

The structural nanomedicine approach has already been applied to developing SNA vaccines for several different cancers, including melanoma, triple-negative breast cancer, colon cancer, prostate cancer and Merkel cell carcinoma. All have shown promise in pre-clinical models, and seven SNA drugs have already entered human clinical trials for a range of diseases.